Immune Response News and Research

RSS

Discovering a molecule that could interfere with SARS-CoV-2 replication

In this interview, News-Medical speaks to Stepan Nersisyan about his discovery of a molecule that could replicate SARS-CoV-2.

22 Sep 2020

Exploring how COVID-19 pandemic trajectory might unfold in the future

Researchers who adapted standard epidemiological models to explore how the COVID-19 pandemic trajectory might unfold in the next five years report diverse scenarios ranging from recurring severe epidemics to elimination.

22 Sep 2020

Impaired cytotoxic T cell response found in in elderly COVID-19 patients

Although people of any age can become infected with SARS-CoV-2, the virus that causes COVID-19, elderly patients face a higher risk of severity and death than younger patients.

22 Sep 2020

Study detects key differences in immune responses of adults and children with COVID-19

The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults.

22 Sep 2020

Strength, duration of immunity will shape the future trajectory of COVID-19

New research suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19.

21 Sep 2020

Novel sequencing method could be useful for COVID-19 research

Researchers at the University of Chicago and the Cleveland Clinic have presented a novel single-cell RNA sequencing method that could be a useful application for research into the current coronavirus disease 2019 (COVID-19) pandemic.

20 Sep 2020

UM receives $33.4 million for development and clinical trials of opioid vaccines

The National Institutes of Health has awarded the University of Montana a five-year, $33.4 million award for the development and clinical trials of opioid vaccines. It is the largest such award in University history.

19 Sep 2020

Enhancing the efficacy of anti-PD-L1 immunotherapy for cancer

For most people, there is no scarier diagnosis than that of cancer. While treatments including chemotherapy and radiotherapy have been used since the 1940s and late 1800s, respectively, immunotherapy has more recently emerged as a viable and successful approach to cancer treatment.

18 Sep 2020

Ineffective immune responses may be responsible for COVID-19 mortality rates in men and the elderly

News-Medical speaks to Dr. Nicole Lieberman about her latest research that discovered delayed immune responses may affect COVID-19 mortality rates.

18 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

T cells on the front line of COVID-19 response

In the new study, published in the journal Cell, the team has found that the uncoordinated responses produced by the immune system, especially in people who are more than 65 years old, maybe the reason why older adults are more at risk.

17 Sep 2020

Biomarker predicts disease severity in COVID-19 patients

Airway cell analyses showing an activated immune axis could pinpoint the COVID-19 patients who will most benefit from targeted therapies.

17 Sep 2020

Study: T cells play a vital role in controlling SARS-CoV-2 during acute phase of infection

Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19. The latest study by researchers at La Jolla Institute for Immunology clearly argues in favor of the immune system.

17 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

UC Davis uses microneedles to deliver gene therapy for retinal diseases

A novel approach to delivering gene therapy for retinal diseases eliminates the need for complex eye surgery and treats more damaged cells than existing methods, a team of UC Davis physicians and veterinary eye specialists has found.

16 Sep 2020

Self-assembling nanoparticles as a way towards next-generation COVID-19 vaccines

In a promising study by US researchers, the receptor-binding domain (RBD) and stabilized spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were displayed on nanoparticles as vaccine antigens and elicited potent immune responses.

16 Sep 2020

Study highlights role of specific protein in the mass production of antibodies

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic.

16 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020